Background: The diagnosis of Alzheimer’s disease (AD) relies on core cerebrospinal fluid (CSF) biomarkers, amyloid beta (Aβ) and tau. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.